Hengrui Medicine fully exercises over-allotment option

Jiangsu Hengrui Medicine (SSE:600276) announced the full exercise of its over-allotment option related to its H-share offering, which was initially listed on the Hong Kong Stock Exchange on May 23, 2025. The over-allotment option, exercised by the joint global coordinators on June 19, 2025, involved 33,677,800 H-shares priced at HKD 44.05 per share. This increases the total H-shares issued from 224,519,800 to 258,197,600, raising additional net proceeds of HKD 1,471.5 million for the company. The stabilization period, related to the global offering, concluded on June 19, 2025. The company plans to allocate the net proceeds according to the uses stated in the prospectus. Post-exercise, A shares represent 96.11% of all shares, while H shares represents 3.89%.